BioCryst Pharmaceuticals BCRX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's accounts payable?
- BioCryst Pharmaceuticals (BCRX) reported accounts payable of $10.96M in Q1 2026.
- How has BioCryst Pharmaceuticals's accounts payable changed year-over-year?
- BioCryst Pharmaceuticals's accounts payable increased by 9.0% year-over-year, from $10.05M to $10.96M.
- What is the long-term trend for BioCryst Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's accounts payable has grown at a -3.3% compound annual growth rate (CAGR), from $18.71M to $15.83M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.